Introduction
Development of drug resistance in tumor cells is a common occurrence, and is the primary reason for failure of chemotherapy. However, the biochemical bases for drug resistance are complex. Nitrogen mustard-type bifunctional alkylating drugs are being used in treatment of various human malignancies for some 40 years. These drugs, including chlorambucil (CBL), bind to a variety of cellular components and induce DNA cross-links which appear to be the critical cytotoxic products responsible for their anti-tumor activity (Begleiter et al., 1996) . A number of biochemical changes could contribute to the development of cellular resistance to CBL and other alkylating drugs. It is clear that tumor resistance to alkylating agents is not related to overexpression of the Pglycoprotein (MDR gene product) or MDR1-related protein (MRP), which is often observed for some other types of drugs (Gottesman and Pastan, 1993) . On the other hand, mechanisms contributing to such resistance may include enhanced metabolism and/or detoxification of the drug (Colvin et al., 1993; Horton et al., 1999) , increased repair of drug-induced DNA damage Mitra and Kaina, 1993; Tano et al., 1997) , and abrogation of apoptosis (Green and Reed, 1998) .
Many antitumor drugs induce apoptosis by triggering cellular biochemical pathways that activate the ICE family of cysteine proteases (caspases; Adams and Cory, 1998; Thornberry and Lazebnik, 1998 ;) via apoptotic protease activating factors (Apaf; Green and Reed, 1998) . Release of Apaf's from the mitochondria is often associated with the opening of mitochondrial permeability transition (mPT) pore, followed by a decrease in the mitochondrial membrane potential (mDC), which in turn may lead to generation of reactive oxygen species (ROS; Green and Reed, 1998; Reed, 1997) . For drug/radiation-induced apoptosis cytosolic forms of cytochrome c (cyt c) is an essential part of a caspase 3 activation complex which consists of cyt c, Apaf-1 and procaspase-9, and cause activation of caspase 3. Execution of apoptosis is associated with cleavage of caspase 3 substrates including poly(ADP-ribose) polymerase (PARP; Green and Reed, 1998; Thornberry and Lazebnik, 1998) .
Several gene products of the Bcl-2 family have been shown to promote or inhibit apoptosis (reviewed in Adams and Cory, 1998) . Constitutive as well as transgenic overexpression of Bcl-2 or Bcl-x L has been shown to inhibit apoptosis (Decaudin et al., 1997; Hu et al., 1998; Yang et al., 1997) . Accumulation of Bak, Bax and/or Bcl-x S in the mitochondrial membrane and/ or their interaction with Bcl-2/Bcl-x L was proposed to enhance opening of the mPT pores and initiate the apoptotic process (Hu et al., 1998; Reed, 1997; Van der Heiden et al., 1997) .
In order to elucidate the involvement of the Bcl-2 family proteins in alkylating drug resistance of tumor cells, we isolated variant clones of the A2780 human ovarian carcinoma cell line after repeated treatment with CBL. These cells, named A2780(100), were tenfold more resistant to CBL than the parent cells (Horton et al., 1999) . We also showed earlier that enhanced CBL detoxi®cation by glutathione-S-transferase (GST), whose level was elevated in A2780(100), could contribute to the resistance to CBL and other DNA crosslinking alkylating agents including melphalan, cisplatin and mitomycin C. However, drug resistance of these cells could not be accounted by the enhanced GST activity alone because these cells were also resistant to etoposide (ETO), an inhibitor of DNA topoisomerase II (topo II) not known to be aected by GST. We, therefore, decided to examine whether enhanced DNA repair was responsible for resistance of A2780(100) to CBL, or whether altered expression of pro-and anti-apoptotic proteins in A2780 and A2780(100) was responsible for the dierence in their drug sensitivity. Our results show that while multiple changes in the levels of Bcl-2 family proteins occurred in both sensitive and resistant cells, deliberate modulation of their levels in stably transfected cells did not signi®cantly aect the IC 50 values of CBL. These results suggest that the critical step in the development of CBL resistance in A2780(100) cells was upstream to the site of action of the Bcl-2 family members, and may involve upregulation of repair of drug-induced DNA damage in the resistant cells.
Results

Induction of apoptosis by chlorambucil in A2780 but not A2780(100) cells
Commensurate with the general observation that chemotherapeutic agents kill tumor cells via the apoptotic pathway, treatment of A2780 with 125 mM CBL resulted in typical apoptotic signals. Figure 1 shows that 48 h after drug treatment, more than 90% A2780 cells were stained in the TUNEL assay indicating extensive DNA fragmentation characteristic of apoptosis. In contrast, A2780(100), which were earlier shown to be highly resistant to CBL (IC 50 =65 mM) in the colony forming assay, were resistant to apoptosis (Horton et al., 1999) . Less than 5% of these cells were TUNEL-positive under the same condition of treatment as for A2780 cells ( Figure 1B ). TUNEL-positive cells were not observed earlier than 24 h after CBL treatment of A2780 cells indicating that the onset of apoptosis occurs much later in A2780 (and many other carcinoma cells) than that observed in leukemic or lymphoma cells (Begleiter et al., 1996) . Similar pattern of apoptosis was observed in A2780 after ETO treatment (data not shown).
Because TUNEL assay may not distinguish between apoptotic and necrotic cells (Stahelin et al., 1998) , we assessed, in parallel experiments, the DNA content of CBL-treated A2780 and A2780(100) cells by propidium iodide staining (Bresnahan et al., 1997) . Histograms generated by¯ow cytometry show that more than 80% A2780 cells are sub-G1 at 48 h after treatment, while drug-treated A2780(100) cells had a cell cycle stage distribution similar to that of the nontreated cells (Figure 1 ).
Loss of mitochondrial membrane integrity due to drug treatment
In addition to CBL's involvement in DNA crosslinking, the drug binds to a variety of cellular macromolecules (Begleiter et al., 1996) ; thus release (100) to CBL-induced apoptosis. A2780 (A,B) or A2780(100) (C and D) cells were mock-treated (A,C) or treated (B,D) with CBL (125 mM) for 1 h and then analysed for apoptosis by TUNEL assay 48 h after drug treatment, as described in Materials and methods. Inset: Flow cytometric analysis of apoptotic cells. Cells were harvested at 48 h after CBL treatment and stained with propidium iodide for uorescence-activated cell sorting to separate G 1 , S, G 2 /M and SubG 1 cell population of cyt c could result from a direct chemical interaction between CBL and pore-forming molecule(s). On the other hand, ETO speci®cally binds to topo II stabilizing the cleavable DNA-topoisomerase complex and does not interact with protein or lipid components of mitochondria (Kamesaki et al., 1993) . We, therefore, examined whether a dierential eect of drug treatment on mitochondrial function in A2780 and A2780(100) could account for their distinct drug sensitivity. First, we investigated morphological changes of the mitochondria by¯uorescence microscopy of CBL-and ETO-treated cells after loading mitochondria with rhodamine 123 (RD123). Kinetic measurements demonstrated that in both cases rounding and enlargement (swelling) of mitochondria occurred in a subset of mitochondria as early as 6 h after drug exposure of both A2780 and A2780(100) cells ( Figure 2B ), relative to mock-treated cells ( Figure  2A ). Drug treatment resulted volume changes and intra-cellular distribution only in a subset of mitochondria and these changes were more extensive and irreversible in A2780, but transient in A2780(100).
There was no signi®cant dierence between CBL-and ETO-induced mitochondrial volume changes and for the time course as well. We did not observe anȳ uorescence associated with other cellular components such as the nuclear or cytoplasmic membranes ( Figure  2A,B) .
Although the mitochondrial volume change and decrease in mDC often coincide during apoptosis (Green and Reed, 1998 ) measurement of the volume change by¯ow cytometry with a¯uorescent probe such as RD 123 (Salvioli et al., 1997) may not be reliable. Therefore, we investigated the immunochemical accessibility of cytochrome oxidase subunit IV, located on the inner membrane of mitochondria (Tsukihara et al., 1996) . It is known that the surface of mitochondrial inner membrane is much larger than that of the outer membrane. Therefore, an increase in matrix volume due to permeability transition after CBL or ETO treatment may result in rupture of the outer membrane. Mitochondria isolated from mocktreated A2780 and A2780(100) cells demonstrated a similar intensity of¯uorescence with both cytochrome oxidase subunit IV antibody and isotype-matched control antibody, indicating an intact outer membrane ( Figure 2C,a,b) . However, from 9 h onwards after drug treatment, increased antibody staining was observed with mitochondria isolated from drug-treated A2780 cells ( Figure 2D,a) , relative to the mitochondria from the mock-treated cells ( Figure 2D,b) . In contrast, mitochondria from ETO-or CBL-treated A2780(100) cells showed only a small increase in¯uorescence intensity after staining with the antibody to cytochrome oxidase subunit IV (data not shown). These results indicate that drug treatment caused a dramatic volume change and disruption of the outer mitochondrial membrane in A2780 cells. It is unlikely that CBL (or ETO) caused release of cyt c by directly reacting with the mitochondrial membrane components, because we did not observe any increase in staining with an antibody to cytochrome oxidase subunit IV when CBL was added to preparations of mitochondria isolated from non-treated A2780 or A2780(100) cells.
Because cyt c released from the mitochondria was shown to trigger apoptosis (Green and Reed, 1998) we examined the presence of cyt c in S-100 fractions of A2780 and A2780(100) cells after treatment with CBL (100 mM) for 1 h. The cells were harvested at dierent time points after treatment and the mitochondrial and cytosolic fractions (S-100) were prepared (Yang et al., 1997) . Western blot analysis demonstrated that a signi®cant amount of cyt c was released into the S-100 fraction of the A2780 cells beginning at 18 h posttreatment, and reaching the maximum level at 48 h. S-100 fractions from the A2780(100) cells did not contain signi®cant amount of cyt c, though at 18 and 24 h post-treatment there was some minor cyt c release which was not evident at later time points. Cyt c was detectable only in the mitochondrial lysates and not the S-100 fraction of mock-treated A2780 or A2780(100) cells (data not shown).
To analyse whether accumulation of cyt c in the S-100 fraction of A2780 cells was involved in activation of caspase 3, we investigated degradation of PARP, a preferred substrate of this protease (Yang et al., 1997) . Exposure of parental A2780 cells, but not of A2780(100) to 100 mM CBL resulted in degradation Eect of CBL treatment on the constitutive and induced levels of DNA repair proteins in A2780 and A2780 (100) The major, primary DNA adduct of CBL is 7-alkylguanine which in a second step reaction generate the cytotoxic crosslinks (Kohn et al., 1966) . Repair of 7-alkylguanine by N-methylpurine-DNA glycosylase (MPG) would prevent cytotoxicity. Similarly, DNA crosslinks induced by BCNU (carmustine) are generated from the primary adduct O 6 -chloroethylguanine which is subject to repair by O 6 -methylguanine-DNA methyltransferase (MGMT; Mitra and Kaina, 1993) . AP-endonuclease (APE) and DNA polymerase b (bpol) are involved in the base excision repair pathway to remove small DNA alkyl adducts (Krokan et al., 1997) . Once DNA cross links are formed, they may be removed by a complex process which involves some nucleotide excision repair enzymes including ERCC-4 (Brookman et al., 1996) . DNA double-strand breaks are repaired by a DNA protein kinase (PK) dependent pathway (Kurimasa et al., 1999) . Many DNA adducts are recognized by the mismatch repair pathway (Mu et al., 1997) .
We, therefore, compared the levels of MPG, MGMT, APE, b-pol, ERCC-4 and the mismatch repair protein MLH1 and Ku80, involved in DNA double-strand break repair in A2780 and A2780(100) with or without treatment with CBL. Western blot analysis (Figure 4) showed, although some of these protein levels are altered after drug treatment, there was no signi®cant dierence in response of the parent and drug resistant cells. Although these results would suggest that enhanced repair of DNA damage induced by CBL and other genotoxic drug was not responsible for the acquired drug resistance of A2780(100), we could not completely eliminate such a possibility because the proteins screened in these experiments might not be limiting in the respective repair processes.
Constitutive and induced levels of pro-and anti-apoptotic proteins in A2780 and A2780(100) after CBL treatment Regardless of whether the primary signal for apoptosis is persistent DNA damage, it now appears that the ratio between anti-and pro-apoptotic proteins determines the cellular response to an apoptotic stimulus at the mitochondrial level (Adams and Cory, 1998; Decaudin et al., 1997; Hu et al., 1998; Van der Heiden et al., 1997; Yang et al., 1997) . We, thus, investigated the levels of expression of Bcl-2 family members in A2780 and A2780(100) cells. We included measurement of APE1 level in these experiments as a sample loading control because, as shown in Figure 4 , the APE-1 level was not aected in A2780 or A2780(100) before or after CBL treatment. Western blot analysis showed that the A2780(100) cells expressed a signi®cantly higher level of Bcl-x L (& eightfold), and Mcl-1 (& fourfold), compared to the A2780 cells ( Figure 5A ). In contrast, the basal expression of pro-apoptotic Bak appeared to be higher (threefold) in A2780 cells when compared to the A2780(100) cells ( Figure 5A) . However, the level of another proapoptotic protein, Bax, was not significantly dierent in A2780 and A2780(100). Interestingly, Bcl-2 was undetectable in both A2780 and A2780(100) lines, although it is abundant in HeLa S3 cell lysates used as a control for testing reactivity of the Bcl-2 antibody ( Figure 5B ). It is not clear why our results are in disagreement with the earlier studies that demonstrated expression of Bcl-2 in A2780 cells (Eliopoulos et al., 1995) . We then investigated whether expression of Bcl-2 family members was modulated as a result of drug treatment. Figure 5C shows that CBL (100 mM) treatment caused a 2.5 ± 3-fold increase in the level of Bak beginning at about 18 h in the A2780 cells. In contrast, no change was observed in A2780(100) cells up to 48 h after CBL treatment. Pro-apoptotic Bax was induced in both A2780 and A2780(100) cells by CBL (100 mM) treatment. However, the kinetics of induction was markedly dierent in these lines ( Figure 5C,D) . A twofold induction was observed at 18 h which increased to ®vefold by 48 h post-treatment in A2780, whereas in A2780(100) cells CBL caused a twofold induction in Bax only at 48 h after treatment. CBL treatment of A2780 cells did not alter the basal level of Bcl-x L , and only a minor change was observed for Mcl-1 in several experiments. In CBL-resistant cells, drug treatment mediated a slight decrease in Bcl-x L level by 18 h, which rebounded by 24 h after treatment. The level of Mcl-1 was not altered in A2780(100) cells during the 48 h period after CBL treatment ( Figure  5C,D) .
To investigate the in¯uence of DNA topoisomerase II inhibitor, (ETO) on A2780 and A2780(100), cells were treated with ETO (40 mM), for various times ( Figure 5C ,D) after drug exposure the cells were harvested to investigate inducible expression of proand anti-apoptotic proteins due to the treatment. In contrast to treatment with CBL, Western blot analysis showed no change in the basal levels of Bax, Bak, Bcl- (100) to etoposide (ETO). Log-phase cells were seeded (200 cells) in 60 mm Petri dishes and 4 h later treated with CBL or ETO for 1 h in serum free-medium. Quadruplet sets of dishes were used for each drug concentration and the experiments were repeated at least three times. Per cent survival was calculated and expressed as the mean+s.e., *, A2780; and &, A2780 (100) x L , or Mcl-1 in response to ETO treatment in either A2780 or A2780(100) cells. Similarly, there was no change in the levels of Bcl-x L and Mcl-1 (data not shown).
Because the CBL and ETO behaved dierently in altering the levels of pro-apoptotic proteins in A2780 and A2780(100), we compared the resistance of A2780(100) to these drugs. Based on the IC 50 values, A2780(100) was approximately tenfold and ®vefold more resistant to CBL and ETO than the parent A2780 cells, respectively (Figure 6 ).
Eects of modulation of Bcl-x L and Bax levels on drug sensitivity of A2780 and A2780 (100) Although the above results suggested that drug resistance of A2780(100) resulted from overexpression of anti-apoptotic Bcl-x L and Mcl-1 along with lower levels of Bak and of Bax relative to that in A2780, it was necessary to test directly the contribution of these proteins to drug sensitivity of A2780(100) or A2780 cells. We, therefore, carried out a series of transfection studies with these cells in order to deliberately modulate expression of Bcl-x L and Bax individually. A2780 cells were transfected with an expression vector for the human Bcl-x L , and stable transfectant clones were selected that had more than &20-fold increase in the Bcl-x L level over those clones transfected with control plasmid only ( Figure 7A inset) . These clones were then compared for sensitivity to CBL and ETO by clonogenic survival assay. Figure 7A shows a typical survival curve and indicates that Bcl-x L provides a small increase in resistance to CBL-induced apoptosis for A2780 cells. The IC 50 of 5.1 mM for A2780 cells increased to 9 mM for the transfectant line. After ETO treatment an increase in per cent of survival of Bcl-x L overexpressing cells were also observed as summarized in Table 1 . In both cases, however the dierences in IC 50 is signi®cantly less than that observed for A2780(100) cells ( Figure 6A,B) . The overexpressed Bcl-x L appeared to be fully functional as signi®ed by slow progression of the cell cycle for A2780 cells (data not shown), an eect of antiapoptotic proteins described previously (Meikrantz and Schlegel, 1995) .
To further investigate the role of Bcl-x L in the maintenance of the drug-resistant phenotype, we transfected A2780(100) cells with anti-sense Bcl-x L expression plasmid. Western blot analysis showed that the Bcl-x L protein level decreased about ®vefold in Bclx L antisense RNA-expressing A2780(100) cells. Control plasmid (pcDNA3) did not alter the Bcl-x L level ( Figure 7B inset) . Figure 7B shows that there was a small decrease in CBL resistance in A2780(100) cells carrying the antisense expressing vector (pcDNA3-Bclx L -as). The IC 50 of A2780(100) cells decreased by 47+4.5%. Similar results were obtained after ETO treatment as summarized in Table 1 . As expected, there was no dierence in drug resistance between A2780(100) and A2780(100) carrying control vector (pcDNA3) only.
That the level of Bax increased (®vefold) significantly in A2780 in response to CBL, suggested an important role of this pro-apoptotic protein. We, therefore, examined the eect of Bax upregulation on CBL resistance in A2780(100). A2780(100) cells were transfected with a Bax expression plasmid and stable transfectant clones were isolated which showed a *20-fold increase in the Bax level relative to the control cells transfected with the empty vector ( Figure 7C inset). However, clonogenic survival assays, summarized in Figure 7C and Table 1, showed that Bax Taken together, these results indicate that alteration in the levels of pro-or anti-apoptotic cells, even if necessary, is not sucient to aect the drug sensitivity pro®les of A2780 and A2780(100) cells. The fact, that ETO treatment while inducing apoptosis did not cause changes in the Bax and Bak levels, suggests that the absolute levels of these proteins are not by themselves determinants for triggering apoptosis, at least in these cells.
Discussion
Because development of drug resistance is invariably responsible for the failure of chemotherapy, and because the nitrogen mustard group of alkylating agents are common components in multidrug therapy protocols for a variety of tumors (Begleiter et al., 1996) , it is important to elucidate the mechanism of resistance to these DNA crosslinking agents. One obvious approach would be to compare the constitutive and drug-induced dierences in various cellular components and functions of the parent and drugresistant variant cells. We selected chlorambucil for the initial studies because this agent, unlike other nitrogen mustards, acts directly without requiring active transport and activation. Our procedure for selecting the resistant variant A2780(100) of the ovarian carcinoma line A2780 involved repeated exposure to CBL. We subsequently showed that the acquired resistance could be signi®cantly reversed by growing A2780(100) over a number of passages without CBL treatment (Horton et al., 1999) . Thus the resistance appears to result from epigenetic changes in the form of altered gene expression, and not from mutations in some critical genes.
Resistance to alkylating agents was previously shown to be caused by their increased detoxi®cation, including conjugation of the drugs with glutathione (Colvin et al., 1993) . In an earlier report, we have shown that a higher level of glutathione-S-transferase (GST) was present in A2780(100) than in the parent cell mostly due to higher expression of GSTm in the resistant line (Horton et al., 1999) . However, the fact that overexpression of GSTm in A2780 did not signi®cantly increase its CBL resistance indicates that the primary mechanism of CBL resistance in A2780(100) was not due to enhanced drug detoxification. Because CBL ®rst induces DNA monoalkyladducts and then alkyl crosslinks, we examined the possible dierences between the parent and drug resistant variants in the levels of several DNA repair enzymes, among which MPG and MGMT are responsible for repair of alkylated base adducts (Mitra and Kaina, 1993) , AP-endonuclease and DNA polymerase b of abasic site in the base excision repair pathway , ERCC-4 for repair of DNA crosslinks (Brookman et al., 1996) , Ku80 for repair of DNA double-strand breaks (Kurimasa et al., 1999) . It is interesting that, as observed earlier, some of these protein, e.g., DNA polymerase b, are activated by drug treatment (Chen et al., 1998 ). However, A2780(100) did not have any comparative increase in the levels of these proteins. These results, however, do not de®nitively exclude involvement of DNA repair in drug resistance. Thus, as discussed later, it is possible that CBL resistance of A2780(100) was due to enhanced DNA crosslink or double-strand break repair in spite of a lack of enhancement of Ku80 in these cells. This is possible if Ku80 (Ku70) is already present in excess in the parent cells.
We propose a simple model for the acquired drug resistance in which expression of multiple genes is altered stochastically due to drug-induced changes in the signaling pathways. The surviving cells would then express, at least over some generations, high levels of proteins that help prevent apoptosis and maintain drug resistance. This would imply that the resistance phenotype is not permanent and its maintenance requires periodic drug treatment as we have actually observed with A2780(100) cells.
It is generally accepted that chemotherapeutic agents kill tumor cells via the apoptotic process in which some proximal drug-induced changes, including DNA damage, trigger activation of the initial step, which in turn, leads to the cascade of a series of proteolytic processes ending in cell death. Apoptosis is indicated by chromatin degradation and generation of subdiploid or Sub-G1 cells (Thornberry and Lazebnik, 1998) . The mitochondria play a key role in apoptosis not only by generating ROS but also by releasing Apaf's (Green and Reed, 1998; Thornberry and Lazebnik, 1998) . Before investigating the mechanism of drug resistance, we con®rmed ®rst that CBL indeed kills A2780 cells via apoptosis. Induction of TUNEL-positive cells, loss of mitochondrial membrane integrity, and degradation of PARP presumably by caspase 3, and generation of sub-G1 cells in the A2780 cell population are consistent with the chain of events in the apoptotic process. As expected, the A2780(100) cells, which did not undergo apoptosis, showed none of those characteristic features after CBL treatment. In an eort to identify which speci®c step or component provided the dierential protection of A2780(100) from apoptosis, we examined both constitutive and inducible levels of several Bcl-2 family members in both A2780 and A2780(100). While the mechanisms of the anti-apoptotic members including Bcl-2, Bcl-x L , Mcl-1, and pro-apoptotic members such as Bax, Bak and Bad are not completely understood, overexpression of Bcl-2, Bclx L or Mcl-1 was shown to prevent drug-induced apoptosis in several cell lines (Eliopoulos et al., 1995; Thornberry and Lazebnik, 1998) . It was, therefore, surprising that our A2780 line, and A2780(100) derived therefrom, do not express Bcl-2 to a detectable extent. However, these cells do express signi®cant levels of Bclx L and Mcl-1. Both A2780 and A2780(100) also express Bax, Bak, and possibly other apoptosis-regulating proteins.
Our observation that higher constitutive levels of Bcl-x L and Mcl-1 were present in A2780(100) than in A2780 was consistent with the expectation that cells with high levels of anti-apoptotic proteins are more resistant to apoptosis. This was further supported by our observation that the drug-sensitive parent cells had a higher constitutive level of Bak or inducible level of Bax, because it is generally accepted that the pro-apoptotic proteins may be involved in drug-induced apoptosis. However, our eorts to establish causal relationship between the altered expression of these pro-and anti-apoptotic proteins and drug sensitivity were unsuccessful. Our results strongly suggest that while Bcl-x L may be important to protect integrity of mitochondria (Green and Reed, 1998; Hu et al., 1998) and for maintenance of the drugresistance phenotype, its downregulation did not result in full reversal of drug resistance in these cells. Overexpression of Bcl-x L in A2780(100) cells did not increase further CBL resistance judged by the IC 50 dose (data not shown). Overexpression of Bcl-x L in sensitive cells, in which the protein level was increased some 20-fold, did not increase the IC 50 value of these cells for CBL signi®cantly. Conversely, overexpression of Bax or downregulation of Bcl-x L in A2780(100) by a considerable extent did not cause a large increase in CBL sensitivity ( Figure 7A,C) .
It is interesting that no change in APE1 level was observed in A2780 cells undergoing apoptosis after CBL treatment. This is in contrast to an earlier observation which showed a signi®cant decrease in APE1 level in promyelocytic HL60 cells undergoing apoptosis (Robertson et al., 1997) . Distinct regulation of APE1 in the two cases may be due to dierent apoptosis pathways in these two dierent cell types.
We have two possible explanations for our results taken together. First, it is possible that the CBL resistant phenotype of A2780(100) resulted from the cumulative eects of overexpression of at least two anti-apoptotic proteins and downregulation of two pro-apoptotic proteins. While the observed changes in the levels of multiple apoptosis-related proteins in the resistant cells was unexpected, the likely reason is that multiple epigenetic changes occurred after repeated drug treatment of these cells. It is possible a change in the level of any single protein in the transfected cells. Even though this change is much larger than that observed endogenously in the naturally selected cells, it may not be enough to tip the balance in favor or against apoptosis because of the need for changing the levels of multiple proteins It should be theoretically possible to test such a prediction; however, the experiments will be technically challenging, and still may not provide unequivocal answers.
The second possibility, which we favor, is that although the levels of appropriate pro-and antiapoptotic proteins are critical in development and maintenance of CBL resistance in A2780(100), the eects of such changes may be overridden by alterations of other components which act at an earlier stage than these proteins in the apoptosis cascade. Thus the critical signals for drug resistance may be upstream to the function of the pro-and anti-apoptotic proteins. For example, the initial signal for apoptosis may be DNA strand breaks in both nucleus and mitochondria, and the resistant cells may have lower DNA damage, as well as more ecient and faster repair of such damage including DNA strand breaks. Our preliminary results that A2780(100) was more resistant than A2780 to g-rays, whose cytotoxicity is due to DNA double-strand breaks, is consistent with this scenario (unpublished observation). Identi®cation of the intracellular signaling processes after CBL treatment and the roles of persistent DNA damage and DNA repair in dierential apoptotic response of A2780 and A2780(100) cells will require further investigation.
Materials and methods
Cell culture and treatment conditions
The A2780 human ovarian carcinoma line, a gift of Dr K Scanlon, was maintained in RPMI-1640 (Gibco-BRL), and A2780(100), isolated as a CBL-resistant clone, was periodically treated with CBL (Horton et al., 1999) . All cultures were routinely tested for mycoplasma contamination using Hoechst 33258 stain.
Apoptosis assay
A2780 and A2780(100) cells were mock-treated or treated with CBL (125 mM) for 1 h as described before (Horton et al., 1999) and allowed to grow at 378C for up to 48 h and then harvested and ®xed with 4% paraformaldehyde. The apoptotic cells were assessed by a¯uorescence tagged Cell Death Detection kit (TUNEL assay; Boehringer-Mannheim) and examined with a Zeiss¯uorescence microscope. Sub-G1 fraction of cell populations were assessed by¯ow cytometry (Becton-Dickinson FACScan) after staining with propidium iodide (Bresnahan et al., 1997) .
Western blot analysis
The cells were lysed as described earlier (Horton et al., 1999) , and after determining the protein concentration of the centrifuged lysates using the Bradford reagent (BioRad), equal amounts of proteins were subjected to SDS ± PAGE (12% acrylamide unless otherwise stated) and visualized by using the ECL (Amersham) Western blotting protocol.
Degradation of poly(ADP-ribose) polymerase (PARP) in CBL-treated A2780 and A2780 (100) cells was determined by harvesting equal number of cells, lysing them in a buer containing 62.5 mM Tris-HCl (pH 6.8), 6 M urea, 10% glycerol, 2% SDS, 0.003% bromophenol blue, and 5% 2-bmercaptoethanol. The lysates from 10 5 cells were loaded for each time points in a 10% SDS ± PAGE gel and PARP degradation was analysed by Western blotting using a anti-PARP monoclonal antibody (C2-10 of D Poirier).
Flow analysis of mitochondrial membrane damage
The mitochondria were pelleted from cell lysates as described previously (Chen and Lash, 1998) and then resuspended in an ice-cold buer (10 mM HEPES-KOH, (pH 7.5); 220 mM mannitol, 68 mM sucrose, 5 mM KH 2 PO 4 , 2 mM MgCl 2 , 5 mM succinate, 2 mM ATP) containing protease inhibitors and pretreated with 1 mg/ ml goat nonimmune IgG (Santa Cruz Biotech., Inc.) for 30 min at 48C to block nonspeci®c antibody binding. After washing once with the same buer, the suspensions were exposed to 1 mg/ml of anti-cytochrome oxidase subunit IV monoclonal antibody (20E8-C12; Molecular Probes, Inc.) for 30 min at 48C. After washing, the mitochondria were resuspended in the same buer containing 1 mg/ml uorescein isothiocyanate-conjugated anti-mouse IgG (Santa Cruz Biotech., Inc.). After 30 min treatment at 48C, the mitochondria were washed, resuspended in buer and the¯uorescence was analysed in a¯ow cytometer.
Clonogenic survival assay
Exponentially growing cells were seeded at a density of 200 cells per 60 mm petri dish and 24 h later treated or mock-treated with increasing doses of CBL or ETO as described previously . Cell survival was calculated from the number of colonies per dish, relative to the control cells. These cells have about 70% plating eciency.
Transfection and expression plasmids
The Bcl-x L cDNA, (a gift of Dr CB Thompson), was subcloned into pcDNA3 (Invitrogen) expression vector in both sense and anti-sense orientations. The A2780 and A2780(100) cells were transfected with the expression plasmids with Lipofectamine (Gibco-BRL) according to the manufacturer's protocol. Individual transfectant clones of A2780 and A2780(100) in which the levels of Bcl-x L and Bax were altered due to transgenic expression were selected on the basis of Western blot analysis. These clones were maintained in RPMI-1640 medium in the presence of 200 mg/ml geneticin (Gibco-BRL).
The human Bax cDNA in the mammalian expression vector pSFFV-neo, (a gift from Dr SJ Korsmeyer), was introduced into A2780(100) cells by calcium phosphate coprecipitation. Geneticin resistant clones were screened by Western blotting and the Bax overexpressing clones were maintained as before.
Statistical data analysis The survival assays were performed at least three times and the standard error was determined by Student's t-test. Statistical signi®cance of IC 50 values was determined by ANOVA test.
Chemicals and reagents Chlorambucil, Etoposide, and Rhodamine 123 were purchased from Sigma-Aldrich and Molecular Probes, Inc. Anti-APE1 polyclonal IgG antibody was described earlier . Anti-Bclx L polyclonal antibody was a gift of Dr CB Thompson.
Monoclonal antibody against Mcl-1 was purchased from Neomarker, Inc., polyclonal antibody against Bax from Pharmingen and monoclonal antibody against Bak from Calbiochem, and monoclonal antibody against Bcl-2 and polyclonal antibody against Ku80 from Santa Cruz Biotechnology, Inc. Monoclonal antibody speci®c for MLH1 were purchased from Calbiochem. Anti-DNA polymerase b was a gift of Dr SH Wilson. Anti-MGMT and anti-MPG antibodies were described earlier (Hazra et al., 1997; Roy et al., 1998) . Anti-ERCC4 antibody was a gift of Dr MP Thelen.
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